Renal and vascular protective effects of telmisartan in patients with essential hypertension

Hypertension Research

Volumn 29, Issue 8, 2006, Pages 567-572

  Morimoto, Satoshi ^a,b   Yano, Yukata ^a   Maki, Kei ^a   Sawada, Katsunori ^a  

^a Ohmihachiman City Hospital   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Antihypertensive dug; Arteriosclerosis; Endothelial dysfunction; Essential hypertension; Renal dysfunction

Indexed keywords

ALBUMIN; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; TELMISARTAN;

ADULT; ANKLE PRESSURE; ANTIHYPERTENSIVE ACTIVITY; ARTERIOSCLEROSIS; ARTICLE; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; MONOTHERAPY; RANDOM SAMPLE; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; TREATMENT DURATION; URINARY EXCRETION; VASCULAR ENDOTHELIUM; VASODILATATION;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARTERIOSCLEROSIS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; VASODILATION;

EID: 33748978039     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.567     Document Type: Article

References (17)

1. Suzuki H, Kanno Y, Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group: Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307-314.
2. Morgan T: Renin, angiotensin, sodium and organ damage. Hypertens Res 2003; 26: 349-354.
3. White WB, Lacourciere Y, Davidai G: Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347-353.
4. Corretti MC, Anderson TJ, Benjamin EJ, et al: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery. J Am Coll Cardiol 2002; 39: 257-265.
5. Motobe K, Tomiyama H, Koji Y, et al: Cut-off value of the ankle-brachial pressure index at which the accuracy of brachial-ankle pulse wave velocity measurement is diminished. Circ J 2005; 69: 55-60.
6. Lacourciere Y, Lenis J, Orchard R, et al: A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3: 295-302.
7. Brenner BM, Cooper ME, de Zeeuw D, et al, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
8. Iino Y, Hayashi M, Kawamura T, et al, Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators: Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21-30.
9. Vanhoutte PM, Mombouli JV: Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis 1996; 39: 229-238.
10. Luscher TF, Barton M: Biology of the endothelium. Clin Cardiol 1997; 20 (11 Suppl 2): II-3-II-10.
11. Clowes AW, Reidy MA, Clowes MM: Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-333.
12. Cheetham C, O'Driscoll G, Stanton K, et al: Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in type II diabetes. Clin Sci (Lond) 2001; 100: 13-17.
13. Higashi Y, Sasaki S, Nakagawa K, et al: Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol 2001; 37: 863-870.
14. Munakata M, Aihara A, Nunokawa T, et al: The influence of one-year treatment by angiotensin converting enzyme inhibitor on baroreflex sensitivity and flow-mediated vasodilation of the brachial artery in essential hypertension - comparison with calcium channel blockers. Clin Exp Hypertens 2003; 25: 169-181.
15. Anderson TJ, Elstein E, Haber H, et al: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35: 60-66.
16. Uchida H, Nakamura Y, Kaihara M, et al: Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545-550.
17. Munakata M, Nagasaki A, Nunokawa T, et al: Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 2004; 17: 1050-1055.